Research programme: macromolecular drug conjugates - Prolynx

Drug Profile

Research programme: macromolecular drug conjugates - Prolynx

Alternative Names: Dual receptor agonists - Prolynx; Hydrogel-exenatide - Prolynx; Hydrogel-octreotide - Prolynx; PEG-exenatide - Prolynx; PEG-octreotide - Prolynx; PLX 039

Latest Information Update: 28 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Prolynx
  • Class Camptothecins; Drug conjugates; Polyethylene glycols
  • Mechanism of Action DNA topoisomerase I inhibitors; Glucagon like peptide 1 receptor agonists; Glucagon receptor agonists; Growth hormone-releasing hormone inhibitors; Somatostatin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes - Acromegaly; Cancer; Type 2 diabetes mellitus

Highest Development Phases

  • Preclinical Ear disorders; Obesity; Type 2 diabetes mellitus
  • Research Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis
  • No development reported Acromegaly; Cancer

Most Recent Events

  • 28 Apr 2018 No recent reports of development identified for preclinical development in Cancer in Japan (Parenteral)
  • 25 Sep 2017 Prolynx receives SBIR grant from National Institutes of Health for development of dual receptor agonist drug conjugates in Type-2 diabetes mellitus, Non-alcoholic fatty liver disease and Non-alcoholic steatohepatitis
  • 25 Sep 2017 Early research in Non-alcoholic fatty liver disease in USA (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top